<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="41541">
  <stage>Registered</stage>
  <submitdate>14/08/2006</submitdate>
  <approvaldate>18/08/2006</approvaldate>
  <actrnumber>ACTRN12606000359538</actrnumber>
  <trial_identification>
    <studytitle>The Myer Foundation Study into Multiple Sclerosis</studytitle>
    <scientifictitle>A randomized placebo controlled double blind pilot trial of unregistered drug MKTVIF75HV on brain magnetic resonance imaging indices in multiple sclerosis</scientifictitle>
    <utrn />
    <trialacronym>HREC 2006.058</trialacronym>
    <secondaryid>Therapeutic Goods Association (TGA) Clinical Trial Notification (CTN): TGA CTN 2006/442</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Relapsing remitting multiple sclerosis</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Multiple sclerosis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Six months of oral MKTVIF75HV (initially 18 000 IU per day). Parallel design. Magnetic resonance imaging (MRI) of the brain with triple dose gadolinium at baseline, 4, 5 and 6 months.</interventions>
    <comparator>Placebo MKTVIF75HV. </comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The total number of new gadolinium enhancing lesions on MRI detected during the 6 months.</outcome>
      <timepoint>The timepoints for enhancing lesion detection are the MRI timepoints noted in "Intervention" above; at baseline, 4, 5 and 6 months..</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The total number of new gadolinium enhancing lesions still present at end study.</outcome>
      <timepoint>6 month timepoint.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The number of new T2 lesions detected during the 6 months, the total cumulative volume of new gadolinium enhancing lesions, the total cumulative volume of new T2 lesions.</outcome>
      <timepoint>The timepoints for detection of MRI lesions are the MRI timepoints noted in "Intervention" above; at baseline, 4, 5 and 6 months.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Relapsing remitting multiple sclerosis, gadolinium enhancing lesion(s) on screening brain MRI scan with triple dose gadolinium.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Primary or secondary progressive multiple sclerosis, pregnancy, clinical relapse or systemic glucocorticoid therapy within 30 days prior to baseline scan, contraindications to closed magnet MRI scanning including claustrophobia, metal foreign body contraindications, allergy to gadolinium. Kurtzke expanded disability scale score greater than 5, past renal calculus, peanut allergy, defined biochemical abnormalities, intercurrent condition which could impair adherence to study protocol.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Randomization made by statistician after participant enrollment in the trial.</concealment>
    <sequence>The statistician will use computer software and stratify by intercurrent specific drug therapy for multiple sclerosis.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>Subjects and assessors will be blinded.</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>24/08/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>Melbourne Health</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>The Myer Foundation</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>Nil</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>To test whether six months' oral treatment with unregistered drug MKTVIF75HV improves magnetic resonance imaging brain scans in people with relapsing remitting multiple sclerosis.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Melbourne Health-Royal Melbourne Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec>2006.058</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Mark Stein</name>
      <address>Department of Diabetes and Endocrinology
The Royal Melbourne Hospital
Parkville 
Victoria 3050</address>
      <phone>+61 3 93427365</phone>
      <fax />
      <email>mark.stein@mh.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Mark Stein</name>
      <address>Department of Diabetes and Endocrinology
The Royal Melbourne Hospital
Parville
Victoria 3050</address>
      <phone>+61 3 93427365</phone>
      <fax />
      <email>mark.stein@mh.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>